[go: up one dir, main page]

WO2008043533A3 - Acylaminoimidazoles et acylaminothiazoles - Google Patents

Acylaminoimidazoles et acylaminothiazoles Download PDF

Info

Publication number
WO2008043533A3
WO2008043533A3 PCT/EP2007/008789 EP2007008789W WO2008043533A3 WO 2008043533 A3 WO2008043533 A3 WO 2008043533A3 EP 2007008789 W EP2007008789 W EP 2007008789W WO 2008043533 A3 WO2008043533 A3 WO 2008043533A3
Authority
WO
WIPO (PCT)
Prior art keywords
acyl
aminoimidazoles
aminothiazoles
diseases
producing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/008789
Other languages
German (de)
English (en)
Other versions
WO2008043533A2 (fr
Inventor
Marcus Bauser
Anja Buchmueller
Degenfeld Georges Von
Elke Dittrich-Wengenroth
Christoph Gerdes
Mark Jean Gnoth
Dirk Gottschling
Stefan Heitmeier
Martin Hendrix
Johannes Koebberling
Dieter Lang
Ulrich Rester
Uwe Saatmann
Adrian Tersteegen
Astrid Bruens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Priority to CA002666177A priority Critical patent/CA2666177A1/fr
Priority to EP07818862A priority patent/EP2079708A2/fr
Priority to JP2009531766A priority patent/JP2010505896A/ja
Publication of WO2008043533A2 publication Critical patent/WO2008043533A2/fr
Publication of WO2008043533A3 publication Critical patent/WO2008043533A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

L'invention concerne des acylaminoimidazoles et acylaminothiazoles et des procédés de production associés ainsi que leur utilisation pour produire des médicaments destinés au traitement thérapeutique et/ou prophylactique de maladies, notamment de maladies cardio-vasculaires, et de préférence de maladies thromboemboliques.
PCT/EP2007/008789 2006-10-11 2007-10-10 Acylaminoimidazoles et acylaminothiazoles Ceased WO2008043533A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002666177A CA2666177A1 (fr) 2006-10-11 2007-10-10 Acylaminoimidazoles et acylaminothiazoles
EP07818862A EP2079708A2 (fr) 2006-10-11 2007-10-10 Acylaminoimidazoles et acylaminothiazoles
JP2009531766A JP2010505896A (ja) 2006-10-11 2007-10-10 アシルアミノイミダゾール類およびアシルアミノチアゾール類

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006048042A DE102006048042A1 (de) 2006-10-11 2006-10-11 Acylaminoimidazole und Acylaminothiazole
DE102006048042.2 2006-10-11

Publications (2)

Publication Number Publication Date
WO2008043533A2 WO2008043533A2 (fr) 2008-04-17
WO2008043533A3 true WO2008043533A3 (fr) 2008-07-03

Family

ID=39184814

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/008789 Ceased WO2008043533A2 (fr) 2006-10-11 2007-10-10 Acylaminoimidazoles et acylaminothiazoles

Country Status (5)

Country Link
EP (1) EP2079708A2 (fr)
JP (1) JP2010505896A (fr)
CA (1) CA2666177A1 (fr)
DE (1) DE102006048042A1 (fr)
WO (1) WO2008043533A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8044069B2 (en) 2008-10-02 2011-10-25 Abbott Laboratories Compounds as calcium channel blockers
US8815869B2 (en) 2010-03-18 2014-08-26 Abbvie Inc. Lactam acetamides as calcium channel blockers
JP2015083542A (ja) * 2012-02-08 2015-04-30 大日本住友製薬株式会社 ３位置換プロリン誘導体
WO2015104605A1 (fr) * 2014-01-08 2015-07-16 Wockhardt Limited Procédé de préparation de rivaroxaban ou d'un sel pharmaceutiquement acceptable de ce dernier
SMT202200134T1 (it) 2018-03-08 2022-05-12 Incyte Corp Composti di amminopirazindiolo come inibitori di pi3k-y
WO2020010003A1 (fr) 2018-07-02 2020-01-09 Incyte Corporation DÉRIVÉS D'AMINOPYRAZINE UTILISÉS EN TANT QU'INHIBITEURS DE PI3K-γ

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009565A2 (fr) * 2002-07-17 2004-01-29 Sanofi-Aventis Derives d'acylaminothiazole, leur utilisation comme inhibiteurs de beta-amyloi
WO2005092864A1 (fr) * 2004-03-23 2005-10-06 Pfizer Products Inc. Composes d'imidazole destines au traitement de troubles neurodegeneratifs
WO2007082666A1 (fr) * 2006-01-12 2007-07-26 Bayer Healthcare Ag Acylaminoimidazoles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009565A2 (fr) * 2002-07-17 2004-01-29 Sanofi-Aventis Derives d'acylaminothiazole, leur utilisation comme inhibiteurs de beta-amyloi
WO2005092864A1 (fr) * 2004-03-23 2005-10-06 Pfizer Products Inc. Composes d'imidazole destines au traitement de troubles neurodegeneratifs
WO2007082666A1 (fr) * 2006-01-12 2007-07-26 Bayer Healthcare Ag Acylaminoimidazoles

Also Published As

Publication number Publication date
JP2010505896A (ja) 2010-02-25
CA2666177A1 (fr) 2008-04-17
WO2008043533A2 (fr) 2008-04-17
DE102006048042A1 (de) 2008-04-17
EP2079708A2 (fr) 2009-07-22

Similar Documents

Publication Publication Date Title
WO2008104306A3 (fr) Amides de 4-aryl-1,4-dihydro-1,6-naphthyridine substitués et utilisation de ceux-ci
WO2009068214A3 (fr) Pipéridines à substitution hétéroaryl
WO2008155069A3 (fr) Oxazolidinones substituées et leur utilisation
IL185804A0 (en) Aminocarbonyl-substituted 8-n-benzimidazoles, method for their production and their use as medicaments
SI2044076T1 (sl) Postopek za pripravo azenapina in vmesni produkti, uporabljeni v tem postopku
WO2008113469A8 (fr) Imidazopyrimidines et triazolopyrimidines substituées
WO2008046581A3 (fr) Composés tétrahydropyrrolopyrazine substitués et leur utilisation dans des médicaments
WO2008060877A3 (fr) Dispositifs médicaux et procédés associés
WO2007088034A3 (fr) Traitement de la sclerose tubereuse
ZA201001015B (en) (Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
EP1858714A4 (fr) Produit metallique recouvert, son procede de production et utilisation dudit procede
IL184694A0 (en) New polymorphous forms of rifazimin, processes for their production and use thereof in the medicinal
ZA201001014B (en) (Cyclopropyl-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
WO2010078900A3 (fr) Nouvelles pyrazolopyridines à substitution aliphatique et leur utilisation
EP2090310A4 (fr) Procédés destinés à prévenir la coloration dans une préparation d'adhésif cutané contenant du donépézil, procédés de réduction de la production d'analogue de donépézil dans une préparation d'adhésif cutané
EP2052847A4 (fr) Presse asservie et son procédé de commande
EP2067597A4 (fr) Produit moulé par injection décoratif bosselé et son procédé de fabrication
AU2007243282A8 (en) Compositions and methods for the treatment of cardiovascular disease
IL179758A (en) Substituted tetrahydro-2h-isoquinolin-1-one derivatives, method for the production thereof and use of the same as medicaments
SI2030612T1 (sl) Farmacevtski sestavek za zdravljenje opeklin in postopek za njegovo izdelavo
WO2008043533A3 (fr) Acylaminoimidazoles et acylaminothiazoles
IL190585A0 (en) Method for the diagnosis of thromboembolic and coronary heart diseases
PL1856988T3 (pl) Sposób wytwarzania i stosowania wyrobów z dodatkiem cukru flawonoidowego
WO2008019782A3 (fr) Dispersions d'agents contenant des nanoparticules d'urée
LT1928255T (lt) Pieno produktų gamybos būdas, tuo būdu gauti produktai ir jų panaudojimas

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2007818862

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2666177

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009531766

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07818862

Country of ref document: EP

Kind code of ref document: A2